Evidence map›Paper›PMID 31209267›Full record

ArticleCancer gene therapy2020

A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models.

Shyambabu Chaurasiya, Nanhai G Chen, Jianming Lu, Nikolas Martin, Yinan Shen, Sang-In Kim, Susanne G Warner, Yanghee Woo, Yuman Fong

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Shyambabu ChaurasiyaDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Nanhai G ChenDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Jianming LuDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Nikolas MartinOttawa Hospital Research Institute, Ottawa, Canada.
Yinan ShenDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Sang-In KimDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Susanne G WarnerDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Yanghee WooDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Yuman FongDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA. yfong@coh.org.
City Of Hope National Medical Center · USOttawa Hospital Research Institute

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Oncolytic viruses have shown excellent safety profiles in preclinical and clinical studies; however, in most cases therapeutic benefits have been modest. We have previously reported the generation of a chimeric poxvirus (CF33), with significantly improved oncolytic characteristics, through chimerization among different poxviruses. Here we report the sequence analysis of CF33 and oncolytic potential of a GFP-encoding CF33 virus (CF33-GFP) with a J2R deletion in lung cancer models. Replication of CF33-GFP and the resulting cytotoxicity were higher in cancer cell lines compared to a normal cell line, in vitro. After infection with virus, cancer cells expressed markers for immunogenic cell death in vitro. Furthermore, CF33-GFP was safe and exerted potent anti-tumor effects at a dose as low as 1000 plaque forming units in both virus-injected and un-injected distant tumors in A549 tumor xenograft model in mice. Likewise, in a syngeneic model of lung cancer in mice, the virus showed significant anti-tumor effect and was found to increase tumor infiltration by CD8+ T cells. Collectively, these data warrant further investigation of this novel chimeric poxvirus for its potential use as a cancer bio-therapeutic.

Indexed as

A549 CellsAnimalsCD8-Positive T-LymphocytesChlorocebus aethiopsFemaleGene DeletionGenes, ReporterGreen Fluorescent ProteinsHumansLung NeoplasmsLymphocytes, Tumor-InfiltratingMiceOncolytic VirotherapyOncolytic VirusesPoxviridaeThymidine KinaseGreen Fluorescent ProteinsThymidine KinaseViral Proteins

Identifiers

PMID31209267
PMCPMC7170804
OpenAlexW2951600248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.